共查询到20条相似文献,搜索用时 15 毫秒
1.
Ronit Elhasid Ronit Nirel Smadar Avigad Gali Avrahami Aya Abramov Dina Attias Nira Arad Ami Ballin Myriam Ben‐Arush Bella Bielorai Yoav Burstein Sarah Elitzur Herzel Gabriel Michal Hameiri‐Grossman Joseph Kapelushnik Dalia Sthoeger Amos Toren Michael Wientraub Isaac Yaniv Shai Izraeli Batia Stark 《Pediatric blood & cancer》2020,67(1)
2.
de Oliveira JC Brassesco MS Scrideli CA Tone LG Narendran A 《Pediatric blood & cancer》2012,59(4):599-604
Acute lymphoblastic leukemia (ALL) is the most common type of pediatric neoplasia. Highly heterogeneous, ALL includes several genetic subtypes with varying clinical outcome. Although, some features are well established as prognostic predictors, the details of the molecular mechanisms underlying different phenotypes are only beginning to emerge. Recently, microRNAs (miRNAs) have been shown to influence a range of physiological processes and, consequently, alterations in their expression and functions have been associated with the development of many cancers, including leukemia. This article aims to review the current state of knowledge of the role of miRNAs on the biology of childhood ALL, also including relevant findings from the adult leukemia literature. 相似文献
3.
First experience of the AML‐Berlin‐Frankfurt‐Münster group in pediatric patients with standard‐risk acute promyelocytic leukemia treated with arsenic trioxide and all‐trans retinoid acid
下载免费PDF全文
![点击此处可从《Pediatric blood & cancer》网站下载免费的PDF全文](/ch/ext_images/free.gif)
Ursula Creutzig Michael N. Dworzak Konrad Bochennek Jörg Faber Christian Flotho Norbert Graf Udo Kontny Claudia Rossig Irene Schmid Arend von Stackelberg Jans‐Enno Mueller Christine von Neuhoff Dirk Reinhardt Nils von Neuhoff 《Pediatric blood & cancer》2017,64(8)
Recently, studies in adults with acute promyelocytic leukemia (APL) showed high cure rates in low‐risk patients treated with all‐trans retinoid acid (ATRA) and arsenic trioxide (ATO), while toxicities were significantly reduced compared to the standard treatment with ATRA and chemotherapy. Here we report about first experience with 11 pediatric patients with low‐risk APL treated with ATRA and ATO. All patients stayed in molecular remission. All suffered from hyperleukocytosis. Two patients experienced reversible severe side effects. One suffered from osteonecroses at both femurs, seizures, as well as posterior reversible encephalopathy syndrome, the other patient had an abducens paresis. 相似文献
4.
Anna van der Does-Van den Berg Claus R. Bartram Giuseppe Basso Yves C. M. Benoit Andrea Biondi Klaus-Michael Debatin Oskar A. Haas Jochen Harbott Willem A. Kamps Ursula Kller Fritz Lampert Wolf-Dieter Ludwig Charlotte M. Niemeyer Elisabeth R. van Wering 《Pediatric blood & cancer》1992,20(6):497-505
Minimal requirements and their rationale for the diagnosis and the response to treatment in childhood acute lymphoblastic leukemia (ALL) were defined in the recently instituted “BFM-Family”-Group, in which the German, Austrian, Dutch, Italian, Belgian, French and Hungarian childhood leukemia study groups cooperate. ALL is defined as ≥ 25% lymphoblasts in the bone marrow; for confirmation of the diagnosis and classification the criteria of the French-American-British (FAB) criteria are retained. For determination of the extent of the disease at diagnosis or relapse the criteria by the Rome Workshop [1986] are recommended: An obligatory panel of monoclonal antibodies for immunophenotyping was defined, as well as criteria for precursor B-ALL and T-ALL. Cytogenetic studies may support the diagnosis and subtyping, and are essential to identify certain patients with a high risk of treatment failure (f.i. t(9;22), t(4;11)). The role of molecular genetics for the diagnosis and the characterization of leukemia and the value of its clinical application needs further elucidation. Relapse was defined as recurrence of evident leukemia in the blood, bone marrow (≥ 25% lymphoblasts) or at any other site (to be confirmed by histological examination). Bone marrow involvement combined with extramedullary relapse was defined as ≥ 5% lymphoblasts in the bone marrow. © 1992 Wiley-Liss, Inc. 相似文献
5.
6.
Paul C. J. Rogers Christopher J. H. Fryer Sherali Hussein 《Pediatric blood & cancer》1982,10(4):385-388
Sixteen children who received cranial irradiation for CNS prophylaxis of leukemia were evaluated for dose of radiation received to the thyroid. Radiation dose received by the thyroid varied between 2.8 to 7.5% of the given dose to the cranium. This is sufficient radiation to increase the risk of long-term thyroid pathology. 相似文献
7.
8.
PEG‐asparaginase allergy in children with acute lymphoblastic leukemia in the NOPHO ALL2008 protocol
下载免费PDF全文
![点击此处可从《Pediatric blood & cancer》网站下载免费的PDF全文](/ch/ext_images/free.gif)
Louise Tram Henriksen Arja Harila‐Saari Ellen Ruud Jonas Abrahamsson Kaie Pruunsild Goda Vaitkeviciene
lafur Gísli Jnsson Kjeld Schmiegelow Mats Heyman Henrik Schrder Birgitte Klug Albertsen 《Pediatric blood & cancer》2015,62(3):427-433
9.
Infectious complications in children with acute lymphoblastic leukemia treated with the Taiwan Pediatric Oncology Group protocol: A 16‐year tertiary single‐institution experience
下载免费PDF全文
![点击此处可从《Pediatric blood & cancer》网站下载免费的PDF全文](/ch/ext_images/free.gif)
Meng‐Ju Li Hsiu‐Hao Chang Yung‐Li Yang Meng‐Yao Lu Pei‐Lan Shao Chun‐Min Fu An‐Kuo Chou Yen‐Lin Liu Kai‐Hsin Lin Li‐Min Huang Dong‐Tsamn Lin Shiann‐Tarng Jou 《Pediatric blood & cancer》2017,64(10)
10.
Giorgio Dini Marida Bartolini Luisa Massimo Adriana Ceci Guido Paolucci Giovanni Calculli Antonio Russo Saverio Magro Carlo Guazzelli Bruno M. Cesana Moncilio Jankovic Fausta Massolo Maria T. Di Tullio Margherita Lo Curto Antonietta Marchi Pier Antonio Macchia Franco Mandelli Girolamo Digilio Domenico Rosati Antonio Acquaviva Enrico Madon Roberto Miniero Paolo Tamaro 《Pediatric blood & cancer》1984,12(3):189-193
In this retrospective multicentric study, we report on early deaths (ie, those that occurred during the first month of treatment) in a total of 943 newly diagnosed ALL pediatric patients registered from 1976 to 1981 at 21 centers of the AIL-AIEOP. Objectives of this study were as follows: (1) to verify the incidence and the cause of early death in a wide population of children with ALL and (2) to elucidate factors associated with early death and therefore to identify “high-risk” groups of patients. Out of the 943 ALL patients, 39 (4.1%) early deaths were registered. Main causes were infection, 20 patients (51.3%); hemorrhage, 11 patients (28.3%); uric acid nephropathy, 2 patients (5.1%); cardiac failure, 3 patients (7.6%); syndrome of inappropriate antidiuretic hormone secretion, 1 patient. Two patients died during the first week of unknown cause. Thirteen factors measured at diagnosis and possibly influencing the early death rate were analyzed. Using the chi-square test, only three of these factors (age, mediastinum status, surface markers) appear to have any significant influence on the early death rate. We also tried to determine how therapy influences this process by analyzing variations in the early death rate, other factors being equal. Significant differences in the early death rates were encountered in AIEOP protocols using different induction regimens. 相似文献
11.
The effect of central nervous system involvement and irradiation in childhood acute lymphoblastic leukemia: Lessons from the NOPHO ALL‐92 and ALL‐2000 protocols
下载免费PDF全文
![点击此处可从《Pediatric blood & cancer》网站下载免费的PDF全文](/ch/ext_images/free.gif)
Mervi Taskinen Trausti Oskarsson Mette Levinsen Matteo Bottai Marit Hellebostad Olafur Gisli Jonsson Päivi Lähteenmäki Kjeld Schmiegelow Mats Heyman 《Pediatric blood & cancer》2017,64(2):242-249
12.
Marion K. Mateos Tracey A. O'Brien Cecilia Oswald Melissa Gabriel David S. Ziegler Richard J. Cohn Susan J. Russell Draga Barbaric Glenn M. Marshall Toby N. Trahair 《Pediatric blood & cancer》2013,60(9):1520-1527
Background
Over the last 25 years, donor source, conditioning, graft‐versus‐host disease prevention and supportive care for children undergoing hematopoeitic stem cell transplantation (HSCT) have changed dramatically. HSCT indications for acute lymphoblastic leukemia (ALL) now include high‐risk patients in first and subsequent remission. There is a large burden of infectious and pre‐HSCT morbidities, due to myelosuppressive therapy required for remission induction. We hypothesized that, despite these trends, overall survival (OS) had increased.Procedure
A retrospective audit of allogeneic pediatric HSCT for ALL was performed in our institution over 25 years. Outcomes for 136 HSCTs were analyzed in three consecutive 8‐year periods (Period 1: 1/1/1984–31/8/1992, Period 2: 1/9/1992–30/4/2001, Period 3: 1/5/2001–31/12/2009).Results
Despite a significant increase in unrelated donor HSCT, event‐free and OS over 25 years improved significantly. (EFS 31.6–64.8%, P = 0.0027; OS 41.8–78.9%, P < 0.0001) Concurrently, TRM dropped from 33% to 5% (P = 0.0004) whilst relapse rate was static (P = 0.07). TRM reduced significantly for matched sibling and unrelated cord blood transplantation (UCT) in Period 3 compared with earlier periods (P = 0.036, P = 0.0098, respectively). Factors leading to improved survival in patients undergoing UCT include better matching, higher total nucleated cell doses, and significantly faster neutrophil engraftment. Length of initial HSCT admission was similar over time.Conclusion
EFS and OS have increased significantly despite heightened HSCT complexity. This survival gain was due to TRM reduction. Contemporary patients have benefited from refined donor selection and improved supportive care. Overall rates of leukemic relapse post‐HSCT are unchanged, and remain the focus for improvement. Pediatr Blood Cancer 2013;160:1520–1527. © 2013 Wiley Periodicals, Inc. 相似文献13.
14.
Angiolillo AL Whitlock J Chen Z Krailo M Reaman G;Children's Oncology Group 《Pediatric blood & cancer》2006,46(2):193-197
BACKGROUND: To determine the response rate and toxicity to gemcitabine administered as 10 mg/m2/min x 360 min weekly for 3 weeks in children with relapsed acute lymphoblastic leukemia (ALL) or acute myelogenous leukemia (AML). Gemcitabine is a deoxycytidine analog that inhibits DNA synthesis and repair and has a broad spectrum of antitumor activity. PROCEDURE: From April 2001 to April 2003, 23 male and 9 female eligible patients were recruited for the Children's Oncology Group (COG) phase II study of Gemcitabine (ADVL0022). RESULTS: One of 20 evaluable patients with ALL and none of 10 evaluable patients with AML had complete responses to gemcitabine; there were no partial responses. Grade 3 or 4 hematologic toxicity and liver toxicity were common during therapy. Only one patient was alive 1 year after entry. The estimated 1-year overall survival probability for the 32 patients was 4% (SE = 3%). CONCLUSIONS: Gemcitabine at the dose and schedule in this trial was not effective for children with relapsed AML or ALL. 相似文献
15.
Mei N. Sitaresmi MD PhD Saskia Mostert MD PhD Chad M. Gundy MS Djauhar Ismail MD PhD Anjo J.P. Veerman MD PhD 《Pediatric blood & cancer》2013,60(10):1593-1597
Background
Event‐free survival of pediatric patients with acute lymphoblastic leukemia (ALL) in Yogyakarta, Indonesia was low (20%). The aim of the study was to evaluate the effectiveness of using a medication diary‐book on the treatment outcome of childhood ALL.Procedure
A randomized study was conducted with 109 pediatric patients with ALL in a pediatric oncology center in Yogyakarta, Indonesia. Both intervention and control groups received a structured parental education program and donated chemotherapy. The intervention group received a medication diary‐book to remind parents and families to take oral chemotherapy and present for scheduled appointments or admissions. Event‐free survival estimate (EFS) at 3 years was assessed.Results
Among pediatric patients with ALL with highly educated mothers (senior high school or higher), the EFS‐estimate at 3 years of the intervention group was significantly higher than the EFS‐estimate at 3 years of the control group (62% vs. 29%, P = 0.04). Among pediatric patients with ALL with low‐educated mothers, no significant difference was found in the EFS‐estimates at 3 years between the intervention and control group (26% vs. 18%, P = 0.86).Conclusions
We conclude that a medication diary‐book might be useful to improve the survival of pediatric patients with ALL in resource‐limited settings, particularly in patients with highly educated mothers. Pediatr Blood Cancer 2013;60:1593–1597. © 2013 Wiley Periodicals, Inc. 相似文献16.
Ramanujachar R Richards S Hann I Goldstone A Mitchell C Vora A Rowe J Webb D 《Pediatric blood & cancer》2007,48(3):254-261
BACKGROUND: Adolescents with acute lymphoblastic leukaemia (ALL) have languished in the shadow of success of the outcome of therapy in childhood ALL. Their treatment has always been incorporated into either paediatric or adult clinical trials depending on the mode of referral and hence there is a need to address an age and risk specific strategy for improving the outcome of this neglected group of patients. This article has summarised the recent and updated retrospective comparative analysis of adolescents treated on the Medical Research Council (MRC) trials. This analysis adds further emphasis to the treatment approach and the merits and limitations of treatment of adolescents on paediatric and adult trials. METHODS: A retrospective comparative analysis of adolescents aged 15-17 years, treated on either MRC ALL97/revised 99 (n = 61), a randomised paediatric trial or UKALLXII/E2993 (n = 67), an adult trial, between 1997 and 2002 was undertaken. RESULT: Results suggest a trend towards a superior outcome on paediatric trials. The 5-year EFS on ALL97 was 65% (95% CI = 52-78%) and on UKALLXII/E2993 was 49% (95% CI = 37-61%; P = 0.01). Multivariate analysis allowing for age and Ph status, diminished the EFS difference, but confirmed a reduced rate of death in remission in patients managed on the paediatric protocol. CONCLUSIONS: Despite limitations in the methodology, comparative studies including our MRC study suggest a consistent advantage for adolescents managed intensively on paediatric trials. Redefining age limits with risk-based strategy and multi-centre collaboration should be considered to improve the survival of young adults. 相似文献
17.
Nobuhiro Suzuki MD PhD Keiko Yumura‐Yagi MD PhD Makoto Yoshida MD PhD Junichi Hara MD PhD Shinichiro Nishimura MD PhD Tooru Kudoh MD PhD Akio Tawa MD PhD Ikuya Usami MD PhD Akihiko Tanizawa MD PhD Hiroki Hori MD PhD Yasuhiko Ito MD PhD Ryosuke Miyaji MD PhD Megumi Oda MD PhD Koji Kato MD PhD Kazuko Hamamoto MD PhD Yuko Osugi MD PhD Yoshiko Hashii MD PhD Tatsutoshi Nakahata MD PhD Keizo Horibe MD PhD 《Pediatric blood & cancer》2010,54(1):71-78
18.
19.